Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with...

Area of Science:

• Cardiovascular Pharmacology
• Metabolic Syndrome Research
• Adipokine Signaling Pathways

Background:

• Elevated circulating fatty acid-binding protein 4 (FABP4) is linked to obesity, insulin resistance, hypertension, and cardiovascular events.
• The impact of pharmacological agents on circulating FABP4 levels remains largely uncharacterized.

Purpose of the Study:

• To investigate the effects of angiotensin II receptor blockers (ARBs) on serum FABP4 concentrations in hypertensive patients.
• To explore the direct effects of ARBs and angiotensin II on FABP4 secretion in adipocytes.

Main Methods:

• Clinical study involving essential hypertensive patients treated with various ARBs (candesartan, olmesartan, valsartan, telmisartan).
• Measurement of serum FABP4 levels, blood pressure, adiposity, lipid profiles, and insulin sensitivity (M value via glucose clamp).
• In vitro study using 3T3-L1 adipocytes to assess FABP4 secretion under different treatments (isoproterenol, insulin, angiotensin II, ARBs).

Main Results:

• ARBs significantly decreased blood pressure and serum FABP4 concentrations (8-20%) without altering adiposity or lipid profiles.
• Candesartan treatment significantly increased insulin sensitivity (M value).
• In vitro, angiotensin II or ARBs did not affect FABP4 gene expression or secretion in adipocytes, while isoproterenol increased and insulin suppressed FABP4 secretion.

Conclusions:

• Treatment with different ARBs similarly reduces circulating FABP4 concentrations in hypertensive patients, indicating a class effect.
• This reduction in FABP4 by ARBs is not mediated by direct blockade of the angiotensin II receptor in adipocytes.
• Decreased FABP4 levels due to ARB therapy may play a role in the suppression of cardiovascular events.